Importance of cellular microenvironment and circulatory dynamics in B cell immunotherapy

被引:435
作者
Gong, Q
Ou, QL
Ye, SM
Lee, WP
Cornelius, J
Diehl, L
Lin, WY
Hu, ZL
Lu, YM
Chen, YM
Wu, Y
Meng, YG
Gribling, P
Lin, ZH
Nguyen, K
Tran, T
Zhang, YF
Rosen, H
Martin, F
Chan, AC
机构
[1] Genentech Inc, Dept Immunol, San Francisco, CA 94080 USA
[2] Genentech Inc, Dept Antibody Engn, San Francisco, CA 94080 USA
[3] Genentech Inc, Dept Assay & Automated Technol, San Francisco, CA 94080 USA
[4] Genentech Inc, Dept Pathol, San Francisco, CA 94080 USA
[5] Scripps Res Inst, Inst Childhood & Neglected Dis, Dept Immunol, La Jolla, CA 92037 USA
关键词
D O I
10.4049/jimmunol.174.2.817
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
B cell immunotherapy has emerged as a mainstay in the treatment of lymphomas and autoimmume diseases. Although the microenvironment has recently been demonstrated to play critical roles in B cell homeostasis, its contribution to immunotherapy is unknown. To analyze the in vivo factors that regulate mechanisms involved in B cell immunotherapy, we used a murine model for human CD20 (hCD20) expression in which treatment of hCD20(+) mice with anti-hCD20 mAbs mimics B cell depletion observed in humans. We demonstrate in this study that factors derived from the microenvironment, including signals from the B cell-activating factor belonging to the TNF family/BLyS survival factor, integrin-regulated homeastasis. and circulatory dynamics of B cells define distinct in vivo mechanism(s) and sensitivities of cells in anti-hCD20 mAb-directed therapies. These findings provide new insights into the mechanisms of immunotherapy and define new opportunities in the treatment of cancers and autoimmune diseases.
引用
收藏
页码:817 / 826
页数:10
相关论文
共 39 条
[1]   The relationship of FcγRIIIa genotype to degree of B cell depletion by rituximab in the treatment of systemic lupus erythematosus [J].
Anolik, JH ;
Campbell, D ;
Felgar, RE ;
Young, F ;
Sanz, I ;
Rosenblatt, J ;
Looney, RJ .
ARTHRITIS AND RHEUMATISM, 2003, 48 (02) :455-459
[2]   Variation in gene expression patterns in follicular lymphoma and the response to rituximab [J].
Bohen, SP ;
Troyanskaya, OG ;
Alter, O ;
Warnke, R ;
Botstein, D ;
Brown, PO ;
Levy, R .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2003, 100 (04) :1926-1930
[3]   Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcγRIIIa gene [J].
Cartron, G ;
Dacheux, L ;
Salles, G ;
Solal-Celigny, P ;
Bardos, P ;
Colombat, P ;
Watier, H .
BLOOD, 2002, 99 (03) :754-758
[4]   Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets [J].
Clynes, RA ;
Towers, TL ;
Presta, LG ;
Ravetch, JV .
NATURE MEDICINE, 2000, 6 (04) :443-446
[5]  
Cyster JG, 2002, ADV EXP MED BIOL, V512, P35
[6]   INVIVO ABROGATION OF SERUM C3 AND C5 BY ADMINISTRATION OF COBRA VENOM FACTOR AND HETEROLOGOUS ANTI-C3 [J].
DRAKE, WP ;
POKORNEY, DR ;
MARDINEY, MR .
JOURNAL OF IMMUNOLOGICAL METHODS, 1974, 6 (1-2) :61-72
[7]   Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis [J].
Edwards, JCW ;
Szczepanski, L ;
Szechinski, J ;
Filipowicz-Sosnowska, A ;
Emery, P ;
Close, DR ;
Stevens, RM ;
Shaw, T .
NEW ENGLAND JOURNAL OF MEDICINE, 2004, 350 (25) :2572-2581
[8]   FcγRIIIa and Fc-γRIIa polymorphisms do not predict response to rituximab in B-cell chronic lymphocytic leukemia [J].
Farag, SS ;
Flinn, IW ;
Modali, R ;
Lehman, TA ;
Young, D ;
Byrd, JC .
BLOOD, 2004, 103 (04) :1472-1474
[9]   CD20 levels determine the in vitro susceptibility to rituximab and complement of B-cell chronic lymphocytic leukemia: further regulation by CD55 and CD59 [J].
Golay, J ;
Lazzari, M ;
Facchinetti, V ;
Bernasconi, S ;
Borleri, G ;
Barbui, T ;
Rambaldi, A ;
Introna, M .
BLOOD, 2001, 98 (12) :3383-3389
[10]  
GOLDSTEIN G, 1985, NEW ENGL J MED, V313, P337